TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
LOS ANGELES, June 28, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Roche Holding AG (“Roche Holding” or the “Company”) (Other OTC:RHHBY) for possible violations of federal securities laws from March 2, 2017 through June 5, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired Roche Holding shares during the Class Period should contact the firm prior to the August 7, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Roche Holding issued materially false and misleading statements and/or failed to disclose that the combination of the Company’s breast cancer drug, Perjeta, and its older treatment, Herceptin, is only marginally more effective than Herceptin alone in preventing breast cancer; and that as a result, Roche Holding’s statements about its business, operations and prospects were materially false and misleading and/or lacked a reasonable bases at all relevant times. When this news became public, Roche Holding’s stock price dropped materially, causing investors harm according to the Complaint.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
